Comparative analysis of business models of top pharmaceutical manufacturing companies: fifi nancial analysis

2020 ◽  
pp. 43-52
Author(s):  
L.E. Yasinskaya ◽  
Keyword(s):  
Comparative Analysis ◽  
Business Models ◽  
Financial Analysis ◽  
Active Pharmaceutical Ingredient ◽  
Pharmaceutical Companies ◽  
Manufacturing Companies ◽  
Revenue Growth ◽  
Commercial Activities ◽  
Pharmaceutical Manufacturers ◽  
Research Procedure

Introduction. Earlier, the comparative analysis of the commercial and investment activities of the companies that play the key roles in the investment processes in the Russian pharmaceutical industry and operate within the four main business models (biotechnological, generic, specialized pharmaceutical companies, active pharmaceutical ingredient (API) manufacturers) has been conducted. No full assessment of the companies’ activitiesis conceivable without a financial analysis of their activities to identify the risks of investment activities. Objective of the study. A detailed comparative analysis of the financial standing of domestic pharmaceutical manufacturers operating within the selected business models for further identification of potential financial risks for investors. Research procedure and article structure. Analysis of RAS statements (forms 1 and 2) of 72 over 500 million revenue companies grouped together as selected business models for the period from 2015 to 2019. Results. The researchers provided a detailed description of the commercial activities of domestic pharmaceutical companies within the business models under consideration. The companies within various business models showed positive revenue growth rates over the past five years. All business models demonstrate consistently high business profitability and a significant share of own capital in the asset profile. Conclusion. The results of the study show the stable financial standing of the pharmaceutical companies within various business models. The biotechnology sector companies that are the most attractive for investments have the highest quality financial standing. The specialized and generic companies show similar consistently strong performance. API manufacturers that the companies with relatively small revenues are actively developing and are attractive to restrained budget investors.

scholarly journals The Impact of Human Capital on Competitive Performance: An Empirical Study on Jordanian Pharmaceutical Companies

2016 ◽  
Vol 12 (4) ◽  
pp. 68
Author(s):  
Mohammad Salameh Yousef ALmasarweh
Keyword(s):  
Human Capital ◽  
Pharmaceutical Companies ◽  
Department Heads ◽  
Manufacturing Companies ◽  
Competitive Performance ◽  
Knowledge And Skills ◽  
Pharmaceutical Manufacturers ◽  
Level Of Significance ◽  
The Impact ◽  
Analyze Data

The study is aimed at knowing the impact of human capital on competitive performance in Jordanian pharmaceutical companies. The study sample consisted of Jordanian human medicines manufacturing companies listed in the Jordanian Association of Pharmaceutical Manufacturers’ records of manufacturing companies for 2015. This amounted to 15 companies. The sampling unit and the analysis included individuals working in these companies from managers to department heads at various administrative levels. To achieve its objectives, the study used descriptive analytical method. This method was applied to collect and analyze data and test hypotheses through a questionnaire, which was used as a tool for the collection of information in the field of study. The study found a number of results, most important of which is: the existence of a statistically significant relationship between human capital (learning; knowledge; and skills) and competitive performance in Jordanian pharmaceutical companies at a level of significance of 0.05. The study recommended that attention be given to human capital in the companies, which will lead to an improvement in the level of the company, as well as an expansion of its market share and maximizing of its strengths.

scholarly journals “A COMPARATIVE STUDY OF FINANCIAL ANALYSIS OF CADILA AND TORRENT PHARMACUTICALS IN GUJRAT STATE”

2020 ◽  
pp. 1-10
Author(s):  
Bhavsinh Dodiya
Keyword(s):  
Comparative Analysis ◽  
Financial Analysis ◽  
Market Price ◽  
Pharmaceutical Companies ◽  
Financial Status ◽  
Social Responsibilities ◽  
Other Information ◽  
Corporate Social ◽  
Current Market Price ◽  
A Current

Estimation of any company real worth is made by the earnings which depend on investments, quality goods, competitiveness, expertise, quality management of company, profitability, capital structure and dividend policy, corporate social responsibilities. For investing in any company many people use a comparative analysis or financial performances of last data to make their buy or sell decisions. We do this because we need to examine a current market price is fair or not. Investor should analyse management, product, strategy, economy, financial status and other information will help to choose that invest or not. Here attempt madeto analyze the comparative analysis through analysis of financial performance of 2 pharmaceutical companies by using a ratio analysis.

Evaluating the Financial Performance Through ‘Consumer Centric Decision’ Approach in Pharmaceutical Companies of Bangladesh: a Business Planning Perspective

2017 ◽  
Vol 9 (1) ◽  
pp. 168
Author(s):  
Md Mostafizur Rahman ◽  
Mahmud Uz Zaman
Keyword(s):  
Market Share ◽  
Swot Analysis ◽  
Financial Analysis ◽  
Pharmaceutical Companies ◽  
Short Term ◽  
The Public ◽  
Investment Choice ◽  
Good Investment ◽  
Business Analysis

Pharmaceuticals agglomerations consistently use their brand image and versatile product portfolios to consolidate their position in the financial sector, which is evident in their continuous profit making and expansion in market share. This paper explores the short-term and long-term investment attractiveness through ‘consumer centric decision’ approach in two selected pharmaceutical companies, Renata Limited and Orion Pharma Limited, of Bangladesh over the last three years’ period. This research adopts a systematic approach which primarily addresses the various concerns of investors to illustrate the decision-making process of the existing and future investors. Using primarily domestic transaction data, this study explores how the leading pharmaceuticals companies of Bangladesh effectively use the wide array of drug portfolios mix with appropriate branding techniques to increase their financial profit and market share simultaneously. Both SWOT analysis and Porters Five Forces Model explore the business analysis of Renata Limited in compare to Orion Pharma Limited that provides a conclusion regarding investors’ decision to invest in Renata Limited. Considering the financial analysis, Renata’s financial liquidity is not very satisfactory and could have been improved further if management is prudent on financial strategy settings. Findings of the business analysis indicate that Renata Limited would be a good investment choice for existing and prospective shareholders based on its opportunities for long term and short term growth and further expansion in developing the market. The results suggest that even lower liquidity coupled with higher interest borrowings can be balanced by posing positive picture to the public shareholders by returning the positive dividend to them.

Benchmarking of TQM practices in the Jordanian pharmaceutical industry (a comparative study)

2018 ◽  
Vol 25 (9) ◽  
pp. 4058-4083 ◽  
Author(s):  
Maysoon Mohammed Yaseen ◽  
Rateb J. Sweis ◽  
Ayman Bahjat Abdallah ◽  
Bader Yousef Obeidat ◽  
Nadia J. Sweis
Keyword(s):  
Quality Management ◽  
Comparative Studies ◽  
Pharmaceutical Manufacturing ◽  
Current Status ◽  
Pharmaceutical Companies ◽  
Manufacturing Companies ◽  
Total Quality ◽  
Critical Factors ◽  
Content Type ◽  
Manufacturing Company

Purpose The purpose of this paper is to establish practical guidelines for benchmarking eight total quality management (TQM) practices vital to pharmaceutical companies’ performance. The paper also proposes the use of an analytic total quality index (TQI) as a benchmarking tool and illustrates the importance and effectiveness of this benchmarking methodology by applying it in two comparative studies of three Jordanian pharmaceutical companies. Design/methodology/approach In order to achieve the above-mentioned purpose, the data were gathered through a questionnaire that was used to evaluate the gap between the ideal and current status of the quality management system and distributed to the quality units from three companies: pharmaceutical manufacturing company, a pharmaceutical manufacturing company working in the same field and a pharmaceutical service providing research services to a pharmaceutical manufacturing companies. And the mean differences between the current and ideal states for the eight critical TQM practices were compared for these two comparative studies using the t-test. Findings Each of the two comparisons reveals statistically significant differences regarding the perceptions of actual and ideal scores for manufacturing and service companies on five out of eight critical factors and, on two out of eight critical factors for manufacturing and manufacturing companies. Practical implications The pharmaceutical companies, regardless of whether they are manufacturing or service company, can adopt benchmarking techniques which were applied in this case study to improve their performance and their product/service quality. Originality/value The consequences of this research can support organization managers and policy makers in effectively benchmarking the identified TQM practices in their organizations using the proposed TQI benchmarking tool.

Managing Complexity in Manufacturing Changeovers: A Sustainable Manufacturing-Oriented Approach and the Application Case Study

2016 ◽  
Author(s):  
Khalid Mustafa ◽  
Kai Cheng
Keyword(s):  
Manufacturing Systems ◽  
Manufacturing Industry ◽  
Business Models ◽  
Sustainable Manufacturing ◽  
Lead Times ◽  
Manufacturing Companies ◽  
Factors Affecting ◽  
Manufacturing Complexity ◽  
Oriented Approach

Increasing manufacturing complexity continues to be one of the most significant challenges facing the manufacturing industry today. Due to these rapid changes in manufacturing systems, one of the most important factors affecting production is recognized as the frequent production setup or changeovers, consequently affecting the overall production lead times and competitiveness of the company. Developing responsive production setup and process capability is increasingly important as product ranges and varieties in manufacturing companies are growing rapidly and, at the same time, production business models are operating more towards being customer-oriented. Furthermore, although different conventional methods have been used to manage complexity in production changeovers, sustainability and competitiveness development in a manufacturing company needs to be scientifically addressed by managing manufacturing complexity. In this paper, a sustainable manufacturing-oriented approach is presented in mind of managing manufacturing changeover complexities. A case study is carried out specifically concerning changeover complexity in a pharmaceutical company, aiming at minimizing complexities in production changeover and waste, increasing plant flexibility and productivity, and ultimately the sustainable competitiveness of the company in managing manufacturing changes.

scholarly journals Dynamics of Business Models in Industry-Wide Collaborative Networks for Circularity

2022 ◽  
Vol 8 (1) ◽  
pp. 3
Author(s):  
Aleš Krmela ◽  
Iveta Šimberová ◽  
Viktorija Babiča
Keyword(s):  
Manufacturing Industry ◽  
Business Models ◽  
Research Strategy ◽  
Collaborative Networks ◽  
Abstract Concept ◽  
Manufacturing Companies ◽  
Legitimacy Theory ◽  
Dynamic Changes ◽  
Financial Reports ◽  
Quantitative Content

Incumbent B2B manufacturing companies join forces and form collaborative networks, called consortia, aiming to increase the circularity of their products. Our research interest lies in the understanding of how the business models (BM) of the companies and the industry are affected by such collaborations in the collaborative networks of the circular economy (CE). Given the exploratory nature of our empirical research, we applied a mixed research strategy of an inductively deductive nature. We carried out case studies in a manufacturing industry field and combined them with quantitative content analyses of the companies’ financial and non-financial reports. Drawing on the assumptions of the Attention-Based View Theory and Legitimacy Theory, we defined and found verbally communicated identifiers of BM elements, CE strategies, and collaborative networks, quantified their occurrences, and transformed them into variables. Using correlation analyses, we determined the tightness and the changes in relationships between the BMs’ elements and CE strategies. We examined the dynamic changes in the structure of BMs and their elements occurring within the implementation of selected CE strategies. Our findings suggest that collaborative networks for CE support an adaptation of the industry’s BMs. The higher-level CE strategies impact the BM more than the lower-level ones. The contribution of our research is in the suggested method of quantification and concretization of an abstract concept of BMs’ elements and their interrelations. This enables an assessment and a direct comparison of BMs, as well as of implemented CE strategies across companies and across industries. Our results also shed more light on the way the companies and industries adapt their BMs towards reaching circularity, as well as on how collaborative networks support such a transition.

Sign in / Sign up

Export Citation Format

Share Document